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Abstract

Objectives To evaluate the association between lupus
severity and cell-bound complement activation products
(CB-CAPs) or low complement proteins C3 and C4.
Methods All subjects (n=495) fulfilled the American
College of Rheumatology (ACR) classification criteria for
SLE. Abnormal CB-CAPs (erythrocyte-bound C4d or B-
lymphocyte-bound C4d levels >99th percentile of healthy)
and complement proteins C3 and C4 were determined
using flow cytometry and turbidimetry, respectively. Lupus
severity was estimated using the Lupus Severity Index
(LSI). Statistical analysis consisted of multivariable linear
regression and groups comparisons.
Results Abnormal CB-CAPs were more prevalent than
low complement values irrespective of LSI levels (62%
vs 38%, respectively, p<0.0001). LSI was low (median
5.44, IQR: 4.77–6.93) in patients with no complement
abnormality, intermediate in patients with abnormal
CB-CAPs (median 6.09, IQR: 5.31–8.20) and high in the
group presenting with both abnormal CB-CAPs and low
C3 and/or C4 (median 7.85, IQR: 5.51–8.37). Odds of
immunosuppressant use was higher in subjects with LSI
≥5.95 compared with subjects with LSI <5.95 (1.60 vs
0.53, p<0.0001 for both). Multivariable regression analysis
revealed that higher LSI scores associated with abnormal
CB-CAPs—but not low C3/C4—after adjusting for younger
age, race and longer disease duration (p=0.0001), which
were also independent predictors of disease severity
(global R2=0.145).
Conclusion Abnormalities in complement activation as
measured by CB-CAPs are associated with increased LSI.

Introduction
SLE is a complex, chronic autoimmune
disease characterised by autoantibody
production and immune system dysregulation resulting in multiorgan inflammation
and potentially damage.
Low complement levels, commonly
found in patients with SLE, generally indicate complement activation, although they

could represent decreased synthesis. Typical
complement assessments include serum
determinations of C3, C4 and in some cases
CH50. Low complement is not included
in the American College of Rheumatology
(ACR) 1997 classification criteria1; however,
it is a component of the criteria put forth by
the Systemic Lupus Erythematosus International Collaborating Clinics2 and the European League Against Rheumatism and ACR3
because it is an important feature of dysregulated immunity in SLE.4
We and others have shown previously that
complement activation can be measured by
the accumulation of C4d on the surface of
haematopoietic cells, including erythrocyte-
bound C4d (EC4d) and B-lymphocyte-bound
C4d (BC4d). These biomarkers, collectively
known as cell-bound complement activation
products (CB-CAPs),5 have superior diagnostic accuracy for lupus6 7 compared with
low serum complement.8 Beyond aiding
in diagnosing SLE, CB-CAPs are useful for
monitoring SLE disease activity as prognostic
biomarkers, although their utility as predictive biomarkers awaits further study.9
Variability in disease manifestations and
severity between different patients as well as
within patients over their disease course is
common. Although an instrument such as the
Safety of Estrogen in Lupus National Assessment - Systemic Lupus Erythematosus Disease
Activity Index (SELENA-
SLEDAI) reflects
disease activity around the time of clinical
evaluation, it does not measure cumulative
disease burden. As cumulative disease severity
can lead to organ damage, instruments that
measure disease severity are important to
identify subjects at risk of major organ involvement. The Lupus Severity Index (LSI) was
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developed as a tool for scoring a subject’s disease severity
based on weighting of ACR classification criteria derived
from one’s treatment history.10 The elements necessary
to score the LSI do not require an in-person examination
and are easily available in medical records and research
datasets. Thus, the LSI can be calculated retrospectively
for large subject cohorts.
In this cross-sectional study of patients with SLE, we
correlated standard complement (C3 and C4) and
CB-CAPs with LSI scores.

and elevated CB-CAPs to LSI with race, gender, age and
disease duration as covariates. Regression analysis of a
subset of patients included medication and renal disease
activity as additional covariates. McNemar’s test was used
to compare CB-CAPs to standard complement testing.
Fisher’s exact test, analysis of variance and Kruskal-Wallis
tests were used for group comparisons as appropriate.
Odds of immunosuppressant use were evaluated by binomial distribution analysis.

Methods
Study population
This study reports a cross-sectional subanalysis of studies
enrolling adult subjects with SLE (n=495) at 17 academic
centres. Central or internal review boards approved the
studies and subjects provided informed consent.
All subjects were diagnosed with SLE and fulfilled the
1997 ACR1 classification criteria. Medication regimens
were available for 438 subjects; 209 were on one or more
immunosuppressants, including methotrexate (n=40),
azathioprine (n=53), mycophenolate (n=105), belimumab (n=12), rituximab (n=2), oral ciclosporin (n=2),
cyclophosphamide (n=3) or intravenous immunoglobulins (n=1).
Venous blood samples were tested at Exagen in our
clinical laboratory accredited by the College of American
Pathologists.

Results
The demographic characteristics of the 495 subjects
included in this study are reported in table 1.
Overall, per cent positivity was 62% for CB-CAPs and
38% for low complement (p<0.0001). Anti-dsDNA was
positive in approximately a third of the population
(table 1).
Median LSI was 5.95 (IQR (5.20–8.17)) and scores
ranged from 3.27 to 9.38 (mean±SD=6.48±1.6). The
majority of subjects were females (91%) and presented
with LSI slightly lower (median 5.9 (5.2–8.2)) compared
with males (median 7.5 (5.3–8.3)). LSI was highest
in Asian subjects (7.1 (5.4–8.3)), followed by African-
American/black (6.7 (5.4–8.2)), Latino/Hispanic (6.6
(5.4–8.2)), other races (5.8 (5.4–8.0)), and lowest in the
Caucasian/white subjects (5.6 (4.9–8.0)) (p<0.001).
Among the 495 subjects, 153 had both low complement
and abnormal CB-
CAPs, 153 had abnormal CB-
CAPs
alone, 37 had low complement alone and 152 presented
with no complement abnormalities (normal complement and normal CB-CAPs). LSI score was highest in the
double positive group, intermediate in the subjects with
low complement or abnormal CB-CAPs only and lowest in
those with neither abnormality (p<0.001) (table 1).
As the LSI distribution across the entire patient population showed two peaks, similar to findings by Bello et al10
(online supplementary figure 1), subjects were divided
into two groups based on LSI: 247 subjects had low LSI
(LSI <5.95, median 5.21 (4.66–5.49)) and 248 had high
LSI (LSI ≥5.95, median 8.17 (7.54–8.51)). Both low
complement and abnormal CB-CAPs were more prevalent
in the high LSI group; interestingly, abnormal CB-CAPs
was more prevalent than low complement in both groups
(p<0.0001 for both) (figure 1).
Binomial distribution analysis showed that the odds
of immunosuppressant use in subjects with LSI ≥5.95
was 1.60 while it was 0.53 in the subjects with LSI <5.95
(p<0.0001 for both).
Univariate analysis results revealed that younger age at
visit, younger age at diagnosis, low complement (C3 and/
or C4), race, positive anti-dsDNA, use of corticosteroids
or immunosuppressants and abnormal CB-CAPs (EC4d
and/or BC4d) associated with higher LSI (table 2, top).
Multivariable linear regression analysis revealed abnormal
CB-CAPs, younger age at visit, longer disease duration, and
race as the strongest predictors of current LSI (table 2,
bottom); low complement (estimate=0.279±0.152,

Lupus severity index
LSI was determined by weighting and summation of ACR
criteria and subcriteria as previously described10 (see
online supplementary material).
Biomarker analysis
Serum C3 and C4 were determined by immunoturbidimetry (The Binding Site, San Diego, California, USA)11 and
were considered low if below the manufacturer’s lower
limits of normal (81.1 and 12.9 mg/dL for C3 and C4,
respectively). Low complement status refers to low C3
and/or low C4.
Complement activation was determined using CB-CAPs
measured by quantitative flow cytometry.11 CB-CAPs were
considered abnormal if levels of EC4d and/or BC4d were
above the 99th percentile of a group of healthy individuals (>14 and >60 net mean fluorescence intensity, respectively).7 8 11 Abnormal CB-CAPs status refers to abnormal
EC4d and/or abnormal BC4d.
Anti-double-stranded DNA (dsDNA) antibodies were
determined by ELISA (Quanta Lite, Inova Diagnostics,
San Diego, California, USA). All serum samples above
301 IU/mL were further tested by indirect immunofluorescence assay (IFA) using the Crithidia luciliae assay
(Nova-
Lite, Inova Diagnostics). Anti-
dsDNA antibodies
were considered positive if confirmed by IFA.
Statistical analysis
Multivariable linear regression analysis was used to
model the relative contributions of low complement
2
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5.95

Anti-dsDNA positivity

History of renal disease

Age at visit

Age at diagnosis

Time since diagnosis

Use of hydroxychloroquine

Use of corticosteroids

Use of immunosuppressants
Lupus Severity Index

9.1

47.7
5.20 to 8.17

61.0

74.7

3.45 to 16.34

19.96 to 38.31

29.26 to 50.93

39.6

31.9

42.8

2.6

18.2

28.7

7.7
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72
7.85

99
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8.60

22.21

31.89
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4
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9
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Both
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55.0
5.51 to 8.37

75.6

80.2
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17.95 to 29.05

24.82 to 41.90

54.2

55.6

31.4

2.6

22.2

33.3
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6.09

92

99

8.11

26.97
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5
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5.31 to 8.20
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2.82 to 19.08
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41.8

30.7

41.2

3.3

19.0

30.7

5.9

88.2

CB-CAPs

13
5.61

18

21

8.05

32.08

38.03

14

12

17

1

5

11

3

34

3

n=37

Only

43.3
4.71 to 7.87

60.0

70.0

2.37 to 13.02

22.08 to 41.64

30.37 to 51.05

37.8

32.4

45.9

2.7

13.5

29.7

8.1

91.9

8.1

Complement

58
5.44

58

102

8.88

33.10

45.69

35

14

84

3

22

33

10

137

15

n=152

Neither

42.0
4.77 to 6.93

42.0

73.9

4.03 to 16.34

24.70 to 45.20

35.03 to 57.39

23.0

9.2

55.3

2.0

14.5

21.7

6.6

90.1

9.9

Demographic information for the total group and each of the groups stratified by CB-CAPs and standard complement positivity (low complement proteins C3 and/or C4). CB-CAPs only group
are subjects with positivity of CB-CAPs, but with normal serum complement proteins C3 and C4. Complement only group are subjects with low complement (C3, C4, or both), but normal
CB-CAPs. Data are presented as number (per cent) or median (IQR). Medication information was available for 438 patients (both n=131; CB-CAPs only n=139; complement only n=30; neither
n=138).
CB-CAPs, cell-bound complement activation products; dsDNA, double-stranded DNA.
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Figure 1 Comparison of low complement and elevated cell-
bound complement activation products (CB-CAPs) by Lupus
Severity Index (LSI) group. Percentage of subjects with low
complement (low serum complement proteins C3 and/or C4)
and elevated CB-CAPs (elevated EC4d and/or BC4d) by LSI
groups.

p=0.098) and gender (estimate=0.438±0.240, p=0.068)
were not significantly associated with the LSI and, therefore, were not included in the model (see online supplementary table 1 for an additional analysis that included
low complement and gender and online supplementary
table 5 for an additional analysis that included positive
anti-dsDNA, low complement and gender). Overall, the
model accounted for 14.5% of the total variability of the
LSI, and abnormal CB-
CAPs alone remained a significant predictor of current LSI (estimate=0.697±0.148,
p<0.0001) after adjusting for age at visit, time since diagnosis and race.
Analysis of a subset of patients for whom medication
information was available (n=438) found that use of
immunosuppressants correlated with higher LSI (online
supplementary table 2) when adjusting for covariates of
CB-CAPs, race, gender, age and disease duration (parameter estimate 0.727, p<0.0001). In a subset of patients
for whom SELENA-
SLEDAI renal activity information
was available (n=446), renal activity correlated with LSI
(parameter estimate 1.937, p<0.0001) after adjusting for
age, disease duration and CB-CAPs (online supplementary table 3). In patients for whom both medication and
renal activity information was available (n=402), CB-CAPs
remained significant predictors of LSI (parameter estimate 0.760, p<0.0001) after controlling for immunosuppressant use, renal activity and age at visit (online
supplementary table 4). Additionally, we show the
progressive effect on the CB-CAPs’ significance as predictors of LSI as additional variables are added to the final
parsimonious model, and the resulting R2 of each model
are detailed in online supplementary table 6.
Discussion
Complement activation has a central role in SLE.5 In
this study, we evaluated the contribution of complement
4

activation and, more specifically, of the classical complement pathway, on SLE severity using the LSI.
In our cross-sectional, multicentre study of 495 well-
characterised lupus subjects, we found that complement
abnormalities (both low C3/C4 and abnormal CB-CAPs)
were more prevalent in subjects with more severe disease
based on their LSI score. When subjects were stratified
by LSI into low and high groups, a higher percentage
of individuals in both groups were CB-
CAPs positive
compared with having low complement. This is consistent
with the higher sensitivity of CB-CAPs compared with low
complement in SLE observed in this and other studies6–8
and indicates that complement activation as measured
by CB-CAPs reflects disease severity more accurately than
low C3/C4. Consistent with these data, although low standard complement C3/C4 associated with elevated LSI,
the association was no longer significant after adjusting
for age and race. However, CB-CAPs correlated with LSI
and remained significant after adjusting for race, age and
time since diagnosis. LSI was highest in Asian subjects,
followed by African-
American/black subjects, Latino/
Hispanic subjects, other and lowest in the Caucasian/
white subjects. These racial differences in LSI are in
agreement with previous data10 and with the fact that SLE
is more aggressive in non-white individuals.12
Younger age at diagnosis and younger age at visit
were associated with higher LSI, as well as longer time
between diagnosis and visit. Due to collinearity between
age at diagnosis and age at visit, age at diagnosis was not
included as a covariate.
Racial and age-related factors are known to have an
impact on lupus severity.12–14 We now show that abnormalities in the complement system and, in particular, classical complement activation as measured by CB-CAPs, are
associated with increased LSI.
As the LSI was derived from immunosuppressant use as
a proxy for disease severity,10 it is not surprising that the
odds of immunosuppressant use was high in the subjects
with more severe disease (LSI ≥5.95). In addition, the
analysis of a subset of patients with available medication
information showed that use of immunosuppressants
correlated (but was not collinear) with LSI scores as
determined by stepwise multivariable analysis.
LSI also correlated with SELENA-SLEDAI renal activity
in a subset analysis. Though these data were not available
for all patients in our dataset, these additional analyses
demonstrated that CB-CAPs remained significant predictors of LSI when adjusting for significant covariates.
The cross-
sectional evaluation of a time-
expanded
concept like the LSI is a limitation of this study. In
addition, disease severity in SLE can be influenced by
multiple factors, while the LSI is based only on weighted
ACR criteria and subcriteria. In the original validation
study, the LSI predicted early mortality, however, it may
not capture all the elements that contribute to disease
severity in SLE.10 Calculation of the Katz Lupus Severity
of Disease index,15 which reflects disease damage, was not

Arriens C, et al. Lupus Science & Medicine 2020;7:e000377. doi:10.1136/lupus-2019-000377

Brief communication
Table 2 Top: Association of LSI with low complement, elevated CB-CAPs, race/ethnicity, gender, age, age at diagnosis and
disease duration (time since diagnosis) as determined by univariate analysis. These variables, except age at diagnosis due to
collinearity with age at visit, were included in a stepwise model building analysis. Bottom: Association of LSI with elevated CB-
CAPs, race/ethnicity, age and disease duration (time since diagnosis), as determined by stepwise multivariable analysis. The
model found that gender and low complement (low C3 and/or C4) were not significant when controlling for the other variables
(p=0.068 and p=0.098, respectively); therefore, they were not included in the final model (R2=0.145)
Top: Univariate analysis
Parameter
estimate

SE

95% CI

P value

Gender
 Male

0.440

0.256

−0.062 to 0.942

0.0859

 Female

Ref

Factor

Race/ethnicity
 Asian

0.709

0.284

0.151 to 1.268

0.0129

 Black/African-American

0.660

0.175

0.316 to 1.003

0.0002

 Hispanic/Latino

0.600

0.203

0.201 to 0.999

0.0033

 Other

0.602

0.461

−0.303 to 1.508

0.1920

 White/Caucasian

Ref

Age at visit

−0.025

0.005

−0.035 to −0.015

<0.0001

Age at diagnosis

−0.035

0.005

−0.045 to −0.024

<0.0001

Time since diagnosis

0.011

0.008

−0.005 to 0.027

0.1793

Low C3 and/or C4

0.648

0.149

0.356 to 0.940

<0.0001

Elevated CB-CAPs

0.958

0.145

0.672 to 1.244

<0.0001

Anti-dsDNA positivity

0.548

0.156

0.241 to 0.855

0.0005

Use of hydroxychloroquine

−0.221

0.180

−0.575 to 0.134

0.2221

Use of corticosteroids
Use of immunosuppressants

0.641
0.893

0.158
0.151

0.330 to 0.952
0.595 to 1.190

<0.0001
<0.0001

CB-CAPs, cell-bound complement activation products; dsDNA, double-stranded DNA; LSI, Lupus Severity Index.

Bottom: Final multivariable model
Parameter
estimate

SE

Factor
Race/ethnicity
 Asian

0.646

0.272

95% CI

P value

0.112 to 1.179

0.0177

 Black/African-American

0.466

0.173

0.127 to 0.805

0.0071

 Hispanic/Latino

0.395

0.197

0.008 to 0.781

0.0456

 Other

0.435

0.441

−0.432 to 1.301

0.3246

 White/Caucasian

Ref

Age at visit

−0.024

0.006

−0.035 to −0.013

<0.0001

Time since diagnosis
Elevated CB-CAPs

0.033
0.697

0.008
0.148

0.016 to 0.049
0.406 to 0.987

0.0001
<0.0001

possible in this study as some of the elements of this index
were not collected for all patients in the dataset.
The findings of this study expand on our previous
work that shows association of CB-CAPs and, in particular, EC4d, with SLE disease activity.9 Taken together,
our data suggest that complement activation as measured

by CB-CAPs parallels disease activity and associates with
disease severity, especially in younger or non-
white
subjects and in those with long-standing disease. However,
data need to be interpreted with caution as the model
accounted for a small fraction (14.5%) of the total variability of the LSI.
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Evaluation of the ability of CB-CAPs to predict future
lupus severity through inception and longitudinal studies
will be important to the field.
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